Concerns about the use of new oral anticoagulants for stroke prevention in elderly patients with atrial fibrillation

Drugs and Aging

Volumn 30, Issue 12, 2013, Pages 949-958

  Stöllberger, Claudia ^a   Finsterer, Josef ^b  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^b NONE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMIODARONE; ANTICOAGULANT AGENT; APIXABAN; CARVEDILOL; CREATININE; CYTOCHROME P450; DABIGATRAN; DILTIAZEM; DIPYRIDAMOLE; MULTIDRUG RESISTANCE PROTEIN; PROPRANOLOL; RIVAROXABAN; SIMVASTATIN; VERAPAMIL; WARFARIN;

AGED; ANTICOAGULATION; CEREBROVASCULAR ACCIDENT; CREATININE CLEARANCE; DEMENTIA; DRUG METABOLISM; DRUG MONITORING; DRUG USE; FALLING; FOOD DRUG INTERACTION; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; MEDICATION COMPLIANCE; PATIENT MONITORING; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; DRUG INTERACTIONS; HEMORRHAGE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE;

EID: 84892921140     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-013-0119-3     Document Type: Review

References (51)

1. Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82:2N-9N.
2. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: The Rotterdam Study. Eur Heart J. 2006;27:949-53.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke. 1991;22:983-8.
4. Marengoni A, Qiu C, Winblad B, et al. Atrial fibrillation, stroke and dementia in the very old: A population-based study. Neurobiol Aging. 2011;32:1336-7.
5. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-67.
6. Scowcroft AC, Lee S, Mant J. Thromboprophylaxis of elderly patients with AF in the UK: an analysis using the General Practice Research Database (GPRD) 2000-2009. Heart. 2013;99: 127-32.
7. Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115:2689-96.
8. Rosenman MB, Baker L, Jing Y, et al. Why is warfarin underused for stroke prevention in atrial fibrillation? A detailed review of electronic medical records. Curr Med Res Opin. 2012;28: 1407-14.
9. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): A randomised controlled trial. Lancet. 2007;370:493-503.
10. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med. 2009;361:1139-51.
11. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med. 2011;365:883-91.
12. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med. 2011;365:981-92.
13. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806-17.
14. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123:2363-72.
15. Höllerl F, Stöllberger C, Finsterer J. Renal function, P-gpaffecting drugs and new anticoagulants for stroke prevention. Int J Cardiol. 2013;168:576-7.
16. Hunchuck JE, Lake JD. Dabigatran for stroke prevention in all patients with atrial fibrillation? Pharmacotherapy. 2011;31: 725-8.
17. Dowling TC, Wang ES, Ferrucci L, Sorkin JD. Glomerular filtration rate equations overestimate creatinine clearance in older individuals enrolled in the Baltimore longitudinal study on aging: impact on renal drug dosing. Pharmacotherapy. 2013;33:912-21.
18. Bene J, Said W, Rannou M, et al. Rectal bleeding and hemostatic disorders induced by dabigatran etexilate in 2 elderly patients. Ann Pharmacother. 2012;46:e14.
19. Cano EL, Miyares MA. Clinical challenges in a patient with dabigatran-induced fatal hemorrhage. Am J Geriatr Pharmacother. 2012;10:160-3.
20. Stollberger C, Rakusan S, Wimpissinger FT, et al. Spontaneous gross haematuria during dabigatran therapy for secondary stroke prevention. Thromb Haemost. 2012;108:579-81.
21. Kernan L, Ito S, Shirazi F, et al. Fatal gastrointestinal hemorrhage after a single dose of dabigatran. Clin Toxicol (Phila). 2012;50: 571-3.
22. Fellows SE, Rosini JM, Curtis JA, et al. Hemorrhagic gastritis with dabigatran in a patient with renal insufficiency. J Emerg Med. 2013;44:e221-5.
23. Wychowski MK, Kouides PA. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother. 2012;46:e10.
24. Legrand M, Mateo J, Aribaud A, et al. The use of dabigatran in elderly patients. Arch Intern Med. 2011;171:1285-6.
25. Dy EA, Shiltz DL. Hemopericardium and cardiac tamponade associated with dabigatran use. Ann Pharmacother. 2012;46:e18.
26. Barton CA, McMillian WD, Raza SS, et al. Hemopericardium in a patient treated with dabigatran etexilate. Pharmacotherapy. 2012;32:e103-7.
27. Lillo-Le Louet A, Wolf M, Soufir L, et al. Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation. Thromb Haemost. 2012;108:583-5.
28. Moore CH, Snashall J, Boniface K, et al. Spontaneous splenic hemorrhage after initiation of dabigatran (Pradaxa) for atrial fibrillation. Am J Emerg Med. 2012; 30:2082e1-2.
29. Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med. 2012;366:864-6.
30. Garber ST, Sivakumar W, Schmidt RH. Neurosurgical complications of direct thrombin inhibitors: catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran. J Neurosurg. 2012;116:1093-6.
31. Chang DN, Dager WE, Chin AI. Removal of dabigatran by hemodialysis. Am J Kidney Dis. 2013;61:487-9.
32. Chen BC, Viny AD, Garlich FM, et al. Hemorrhagic complications associated with dabigatran use. Clin Toxicol (Phila). 2012;50:854-7.
33. Nguyen TM, Phelan MP, Werdich XQ, et al. Subconjunctival hemorrhage in a patient on dabigatran (Pradaxa). Am J Emerg Med. 2013;31:455e3-5.
34. Dumkow LE, Voss JR, Peters M, et al. Reversal of dabigatraninduced bleeding with a prothrombin complex concentrate and fresh frozen plasma. Am J Health Syst Pharm. 2012;69:1646-50.
35. Lal Y, Van Heukelom J. Dabigatran, a cause of hematologic emergency. Am J Med Sci. 2013;346:259.
36. Maddry JK, Amir MK, Sessions D, et al. Fatal dabigatran toxicity secondary to acute renal failure. Am J Emerg Med. 2013; 31:462e1-2.
37. Freshour JE, Hudson JQ, Stevens AB, et al. Epistaxis associated with dabigatran in an elderly patient with reduced creatinine clearance. Am J Health Syst Pharm. 2012;69:1184-6.
38. Stollberger C, Zuntner G, Bastovansky A, Finsterer J. Cerebral hemorrhage under rivaroxaban. Int J Cardiol. 2013;167:e179-81.
39. Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013;76:455-66.
40. Wang L, Zhang D, Raghavan N, et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010;38:448-58.
41. Marchetti S, Mazzanti R, Beijnen JH, et al. Concise review: clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist. 2007;12:927-41.
42. Nobili A, Marengoni A, Tettamanti M, et al. Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study. Eur J Intern Med. 2011;22:597-602.
43. Sanders NA, Ganguly JA, Jetter TL, et al. Atrial fibrillation: an independent risk factor for nonaccidental falls in older patients. Pacing Clin Electrophysiol. 2012;35:973-9.
44. Solayar GN, Walsh PM, Mulhall KJ. The effect of a new direct factor Xa inhibitor on human osteoblasts: an in-vitro study comparing the effect of rivaroxaban with enoxaparin. BMC Musculoskelet Disord. 2011;12:247.
45. Stollberger C, Finsterer J. Concerns about storage and application of dabigatran and rivaroxaban. Eur J Clin Pharmacol. 2013;69: 739-40.
46. Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012;18:527-39.
47. Diug B, Evans S, Lowthian J, et al. The unrecognized psychosocial factors contributing to bleeding risk in warfarin therapy. Stroke. 2011;42:2866-71.
48. Spyropoulos AC, Douketis JD, Gerotziafas G, et al. Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy. J Thromb Haemost. 2012;10: 692-4.
49. Harenberg J, Marx S, Weiss C, et al. Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban. J Thromb Haemost. 2012;10:1433-6.
50. Khan TI, Kamali F, Kesteven P, et al. The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation. Br J Haematol. 2004;126:557-64.
51. Kagansky N, Knobler H, Rimon E, et al. Safety of anticoagulation therapy in well-informed older patients. Arch Intern Med. 2004;164:2044-50.